Intranasal Sumatriptan as First-Line Therapy for Pediatric Migraine in Emergency Departments

Study Background and Research Question

Pediatric migraine represents a significant clinical and socioeconomic burden, with headaches being a frequent reason for emergency department (ED) visits among children and adolescents. While outpatient guidelines exist for migraine management—including oral analgesics and triptans—these recommendations often fall short for youth presenting to the ED, who have typically failed at-home therapies and present with more severe or prolonged symptoms. As a selective serotonin 5-HT1B/1D receptor agonist, sumatriptan is established in adult migraine protocols, but its use in pediatric ED settings remains limited, especially in the intranasal (IN) formulation. The central research question in this study was whether IN sumatriptan could serve as a practical, effective, and resource-efficient first-line intervention for pediatric migraine in the ED setting according to the reference study.

Key Innovation from the Reference Study

The critical innovation in this research lies in the structured evaluation of an ED migraine pathway utilizing IN sumatriptan as a first-line abortive therapy for pediatric patients. Unlike prior reports focused on outpatient or oral triptan use, this study systematically characterized not only the clinical efficacy but also the operational impact—such as length of stay (LOS) and ED charges—of adopting IN sumatriptan in a real-world acute care context. This approach bridges a major gap in pediatric emergency medicine, where evidence-based acute interventions tailored to the needs of children and adolescents have been lacking.

Methods and Experimental Design Insights

The investigators conducted a retrospective chart review at a single tertiary pediatric ED, analyzing records from October 2016 to February 2020. The cohort included 558 patients aged six to 21 years (66% female), all managed according to a standardized ED migraine pathway. Data collected included patient demographics, clinical presentation, treatment patterns, pre- and post-treatment pain scores, discharge prescriptions, LOS, ED charges, and rates of unexpected return visits. The primary focus was on the subset of patients receiving IN sumatriptan, with comparative analyses regarding intravenous (IV) intervention requirements and associated resource utilization.

Core Findings and Why They Matter

The study found that 48% of eligible patients received IN sumatriptan as first-line therapy. Among these, the median pretreatment pain score was 7 (IQR: 5–8), which decreased to a median of 2 (IQR: 0–4) after intervention, indicating substantial symptom relief. Furthermore, 36% of patients treated with IN sumatriptan were prescribed oral sumatriptan at discharge, reinforcing its role in ongoing migraine management. Notably, the requirement for IV access—often necessitated by alternative abortive agents—was associated with significantly longer LOS and higher ED charges. These results suggest that IN sumatriptan not only provides effective acute symptom control but also streamlines ED workflow and reduces healthcare costs as reported by the reference study.

These findings are particularly meaningful for the field of pediatric migraine research. They demonstrate that a selective 5-HT1B/1D receptor agonist can be safely and efficaciously deployed in acute care, supporting broader serotonergic signaling research and encouraging further protocol optimization for youth populations.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on the utility of sumatriptan and its receptor selectivity in migraine and inflammation research. For example, Sumatriptan Succinate: Receptor Agonism and Anti-Inflammatory Evidence underscores the compound's high affinity for 5-HT1B/1D/1F receptors and its anti-inflammatory actions, which are relevant to both clinical efficacy and mechanistic studies. Similarly, Sumatriptan Succinate: Applied Workflows for Serotonergic Signaling details optimized laboratory protocols for in vitro and in vivo models, emphasizing experimental reproducibility and data integrity. Together, these resources contextualize the clinical findings by linking receptor pharmacology and signaling pathway modulation to observed therapeutic outcomes in pediatric migraine protocols.

Moreover, Sumatriptan Succinate: 5-HT1B/1D Agonist for Migraine Research highlights the benchmark status of this agent for dissecting serotonergic mechanisms, which underpins its translation from laboratory research to acute clinical application, as evidenced in the ED study. These internal articles reinforce the centrality of 5-HT1 receptor agonism in both experimental and translational migraine research.

Limitations and Transferability

While the study offers valuable insights, certain limitations must be acknowledged. The retrospective, single-center design limits generalizability; practice patterns and patient demographics may differ in other ED settings. Additionally, the study did not directly compare IN sumatriptan to other first-line therapies in a randomized manner, nor did it systematically evaluate adverse effect profiles in the pediatric population. The reliance on chart review may also underestimate treatment nuances or minor adverse events. Finally, the study period predates recent changes in clinical practice, potentially affecting protocol transferability to contemporary settings.

Despite these limitations, the core finding—that IN sumatriptan is feasible, effective, and operationally advantageous as a first-line therapy—holds promise for adaptation in similar pediatric emergency contexts, especially where rapid symptom resolution and minimization of invasive procedures are prioritized.

Protocol Parameters

• Patient age range: 6 to 21 years (as per retrospective cohort in the reference study).
• IN sumatriptan dosing: Specific dosing regimens were not detailed in the article, but clinical protocols typically use age- and weight-based intranasal doses; consult current pediatric guidelines for precise recommendations.
• Pain score monitoring: Median pre-treatment pain score: 7 (IQR: 5–8); post-treatment: 2 (IQR: 0–4).
• Discharge prescription: 36% of those receiving IN sumatriptan were prescribed oral sumatriptan for ongoing management.
• Workflow suggestion: Minimizing IV access for abortive therapy may reduce ED length of stay and cost.

Research Support Resources

For laboratory and translational research on serotonergic signaling or migraine mechanisms, researchers can utilize Sumatriptan (SKU B4981), a highly selective 5-HT1 receptor agonist validated in both in vitro and in vivo models. APExBIO’s compound supports workflows ranging from cellular inflammation assays to preclinical migraine research, with protocol flexibility for dose, solubility, and metabolic studies. For additional guidance on experimental design or troubleshooting, internal articles such as Sumatriptan Succinate: Applied Workflows for Serotonergic Signaling provide stepwise recommendations for maximizing reproducibility and impact.